Detalhe da pesquisa
1.
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Eur Heart J
; 43(16): 1554-1565, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34922353
2.
Cortical Activation Patterns Correlate with Speech Understanding After Cochlear Implantation.
Ear Hear
; 37(3): e160-72, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26709749
3.
A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins.
J Cardiovasc Pharmacol Ther
; 27: 10742484221138284, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36420979
4.
Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE.
Arch Med Sci
; 18(2): 285-292, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35316922
5.
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.
Eur J Prev Cardiol
; 28(17): 1864-1872, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624041
6.
Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES.
Can J Cardiol
; 38(10): 1542-1549, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644332
7.
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
Eur J Prev Cardiol
; 29(14): 1842-1851, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708715
8.
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes.
J Clin Lipidol
; 16(5): 747-756, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153281
9.
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
Am J Med
; 135(7): 915-918, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296402
10.
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.
Diabetes Care
; 44(5): 1219-1227, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722880